Medicare telehealth got a two-year extension. The cliff it keeps dodging remains.
The pandemic-era rules letting Medicare patients see a doctor from home, anywhere in the country, are now locked in through the end of 2027 — the longest extension since they were created.
The Consolidated Appropriations Act, 2026, signed 3 February, extended key Medicare telehealth flexibilities through 31 December 2027 — the longest single extension since the flexibilities were first created as a temporary pandemic measure in 2020, and a rare instance of Congress acting before, rather than after, a funding deadline actually hit.
What was actually at stake
The Medicare telehealth flexibilities in question let patients receive covered telehealth visits from anywhere in the US and its territories, including from home, rather than being required to travel to a specific originating site like a rural clinic — the pre-pandemic default that the temporary flexibilities suspended. Those flexibilities have technically been temporary since 2020, repeatedly extended through short-term legislation rather than made permanent, which created a recurring pattern health policy observers came to call the "telehealth cliff": a hard expiration date, followed by last-minute Congressional action to extend it again, sometimes retroactively after a brief lapse.
How this extension compares to the pattern that preceded it
The previous extension, passed after a government shutdown, had only pushed the deadline to 30 January 2026 — a matter of weeks, not years. This time, the same Consolidated Appropriations Act that funded NIH and other health agencies for FY2026 also carried a telehealth provision extending flexibilities nearly two full years past that prior deadline, through the end of 2027. The bill also included a five-year extension — separate from and longer than the two-year telehealth extension — for the acute hospital care at home waiver, the program that lets hospitals treat patients who would otherwise be admitted in their own homes instead, with Medicare covering it as though it were inpatient hospital care.
Why "through 2027" isn't the same as "permanent"
This remains an extension, not a permanent change to Medicare telehealth policy — the underlying temporary structure created in 2020 is still temporary, just extended further out than before. Nothing in this legislation converts telehealth flexibilities into a permanent feature of Medicare law, which means the same cliff dynamic that has produced repeated last-minute extensions since 2020 is still structurally in place, just deferred to a later date. A longer runway reduces how often Congress has to act, but it doesn't remove the need to act eventually.
What this means in practice through 2027
For the roughly two years this extension covers, Medicare patients and providers can plan around telehealth access without the near-term uncertainty that came with the shorter extensions of 2024 and 2025 — a meaningful practical difference for health systems that had been reluctant to invest in telehealth infrastructure while coverage rules could lapse on short notice. The hospital-at-home waiver's five-year extension goes further, giving that specific program a longer planning horizon than telehealth flexibilities got.
What to watch next
Whether Congress uses this longer window to pursue a permanent telehealth statute before the 2027 deadline arrives, or whether the cliff dynamic simply resumes on a longer cycle — and how utilization data over the next two years, now collected under stable rather than uncertain coverage rules, shapes that eventual permanent-versus-temporary debate.
Sources
- Congress Extends Medicare Telehealth Flexibilities Through 2027 — American Bar Association , February 5, 2026
Prior authorization delays care. A federal audit shows some denials are wrong.
Physician surveys report delays and abandoned treatment; those are self-reported. A harder number: a federal audit found 13% of Medicare Advantage denials met Medicare's own coverage rules.
The $35 insulin cap is federal law only for Medicare. Gaps remain.
Medicare's cap is statutory; the commercial version is a voluntary manufacturer promise with conditions. Before the caps, 1.3 million adults rationed insulin because of cost.
Medicare's first negotiated drug prices cut 10 drugs 38% to 79%, from 2026
The prices apply only to 10 drugs, only in Medicare, and only from January 2026. Here is exactly which drugs, by how much, and who actually sees the difference.
US brand-name drug prices average more than four times those abroad
Across all drugs, US prices are 2.78 times those in 33 other wealthy countries. The gap is not that Americans use more medicine — it is that no one sets the launch price.